Hyperinsulinaemic hypoglycaemia (HH) is also classically referred to as "nesidioblastosis". Heterogeneous clinical manifestation of the disease causes risk of late diagnosis or even misdiagnosis. In infants and children, it can lead to serious and permanent damage to the central nervous system, which leads to the manifesting mental retardation. HH is characterised by unregulated insulin secretion from pancreatic β-cells. This effect has been correlated with nine genes: ABCC8, KCNJ11, GCK, GLUD-1, HADH1, SLC16A1, HNF4A, HNF1A, and UCP2. Mutations in these genes were found in approximately 48% of cases. The genetic background of the remaining cases is unknown. Understanding the genetic basis of familial hyperinsulinism has changed the early look at the disease. It has allowed for the differentiation of specific types of the disease. Depending on which of the nine disease-associated loci bears a pathogenic mutation, they differ in phenotype and pattern of inheritance. This review provides a brief overview of the genetic mechanisms of HH and its possible clinical presentations. 
Introduction
Hyperinsulinaemic hypoglycaemia has classically been referred to as "nesidioblastosis" in children only, but in later reports also cases in adults have been described, with nesidioblastosis being a more general term, designating morphologic changes in the pancreas, which lead to hyperinsulinaemia, without the presence of an insulinoma [1] . Neonatal and children's hypoglycaemia, if diagnosed late, can lead to serious and permanent damage to the central nervous system (CNS), which leads to manifesting mental retardation [2] . There are many possible reasons of hypoglycaemia, including temporary causes related to the neonatal period, such as the temporary delay in the adaptation to starvation, as well as permanent causes as a result of metabolic or endocrine disorders caused by a disease. In both cases, the most common cause of hypoglycaemia is hyperinsulinism. Familial hyperinsulinism (FHI) occurs at a rate estimated at 1:50 000 [3] in the European population. In most patients symptoms of hypoglycaemia appear shortly after birth, although in some cases the first episodes are observed in late infancy or early childhood. In contrast to the typical symptoms of hypoglycaemia observed after a period without food (fasting), in people with
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familial hyperinsulinism symptoms can also occur after a meal or exercise. The severity can vary significantly between patients, even between members of the same family [4] .
Very often the disease is diagnosed late; unconsciousness and vegetative symptoms that repeat over a couple of years are diagnosed as epilepsy, and patients are treated with anticonvulsants. The consequences of an incorrect diagnosis and lack of proper causality management are irreversible changes in the central nervous system (CNS). The confirmation of hypoglycaemia (blood glucose less than 45 mg/dL) with concomitant hyperinsulinism (insulin level above 6 μU/mL) allows the diagnosis of endogenous hyperinsulinaemia. However, based on blood glucose and insulin levels, an unambiguous statement is not possible; it does not, for example, distinct between an insulin-producing pancreatic insulinoma and diffuse β cell proliferation. Widely available visualisation methods like ultrasound (including endoscopic -EUS), computed tomography, arteriography, and magnetic resonance do not allow clarification of the diagnosis. They are useful only in some cases of hyperinsulinaemic hypoglycaemia, as they allow for the detection of insulin-producing tumours. In other cases, for differentiate diagnosis and the management process, genetic studies may be useful.
Understanding the genetic basis of familial hyperinsulinism changed the early look of the disease. It allowed for the differentiation of specific types of the disease, named FHI. Depending on which of the nine disease-associated loci bears a pathogenic mutation, they differ in phenotype and pattern of inheritance.
Mechanism of insulin secretion
The regulation of insulin secretion from pancreatic β cells is a complex process involving both internal and external stimuli. These include nutrients, hormones, neurotransmitters, and drugs. The main stimulus that activates insulin secretion from β-cells is an elevated glucose level in blood. In the normal case insulin secretion induced by glucose changes is carried out in two phases. In the first there is a "thrust" of insulin in the first few minutes after the cells become exposed to a higher concentration of glucose; in the second the secretion is slow and steady. The molecular mechanism involved in the regulation of phase secretion is essential, and it can briefly be presented as follows [5] : 1. Glucose is transported into pancreatic β cells by facilitated diffusion through the transport protein GLUT2. 2. Intracellular glucose is metabolised with the participation of glucokinase (GCK) to ATP.
3. The increased ATP:ADP ratio inhibits the ATPdependent membrane potassium pump (K-ATP), which leads to depolarisation of the cell membrane. 4. The change of the membrane's electrical potential leads to opening of calcium channels (VDCC) and the influx of calcium into the cell. 5. Elevated levels of cytosolic calcium ions trigger the exocytosis of insulin. Insulin secretion can be effected by oxidation of glucose by glucokinase or leucine-stimulated oxidation of glutamate through glutamate dehydrogenase (Fig. 1) .
Currently, there are nine known genes, the mutations of which are highly associated with familial hyperinsulinism (Table I ). These are as follows: -ABCC8 encoding sulfonylurea receptor 1 (SUR-1); -KCNJ11 encoding a subunit of the pump potassium channel (Kir 6.2); -GCK encoding glucokinase (GCK); -GLUD-1 encoding glutamate dehydrogenase (GDH); -HADH1 encoding 3-hydroxyacyl-CoA dehydrogenase of short-chain fatty acids (SCHAD); -SLC16A1 encoding monocarboxylic acids transporter 1 (MCT1); -HNF4A encoding hepatocyte nuclear factor 4 alpha; -HNF1A encoding hepatocyte nuclear factor 1 alpha; -UCP2 encoding uncoupling protein 2.
ABCC8/KCNJ11
ATP-dependent potassium pump is a heterooctamer composed of four Kir6.2 subunits building the ion channel and four regulatory SUR-1 subunits. Mutations in genes ABCC8 or KCNJ11 lead to loss of protein function. These are the most common cause of hyperinsulinism [6] . They constitutively close the pump, regardless of the concentration of ATP, which in turn causes a constant release of insulin.
Histologically, FHI can be divided into diffuse and focal type [7] . The first is characterised by β-cell malfunction throughout the pancreas, whereas in the second the occurrence of abnormal cells is limited to a small area. The difference between the forms is also evident at the genetic level. The diffuse form is most often caused by recessive mutations in ABCC8 or KCNJ11, while in the focused form heterozygous germline mutations are observed, which are inherited from the father, with a simultaneous loss of the maternal chromosome 11 in the region 11p15.1 to 11p15.5 [8] . The loss of that region in pancreatic progenitor cells is compensated by the duplication of genetic material of the father (somatic paternal uniparental disomy) [9] .
Treatment of the focused form is based on the localisation of the lesion by positron emission tomography with 18-fluoro-L-dihydroxyphenylalanine (18F-DOPA-PET-CT) and its surgical removal. In case of the diffused • severe form of neonatal hypoglycaemia [48, 49] • diffuse FHI** [6] -dominant:
• milder form [48, 49] • focal FHI -caused by a paternal mutation of one of the genes and a specific loss of maternal alleles [8] Dominant, activating [10, [14] [15] [16] Dominant, activating [4, 19] Relatively mild FHI, may escape recognition in infancy [20] Recessive, loss of function [4, [25] [26] [27] [28] Dominant, increased expression [29] Dominant, loss of function [35] Also associated with MODY1 (HNF4a) and MODY3 (HNF1a) [35] Dominant, loss of function Characteristic Large birth weight [4] Increased risk of diabetes in adulthood [4] Normal birth weight [15] Hyperammonaemia [21] Leucine-dependent protein-stimulated hypoglycaemia [4] Elevated urinary 3-hydroxyglutaric acid excretion [4] Leucine-dependent protein-stimulated hypoglycaemia [25] hypoglycaemia after intensive exercise [29] Large birth weight [34] *Cases with dominant KATP mutations may be responsive to diazoxide [48, 49] . **Most cases. Dominant diffuse FHI is also being observed [6] PRACE POGLĄDOWE form, total pancreatectomy is the method of choice, which, however, leads to diabetes. Another possibility is pharmacological treatment. This treatment must be continued over the lifetime of the patient, is not necessarily completely effective, and may cause many side effects.
GCK
Glucokinase catalyses the phosphorylation of glucose to glucose-6-phosphate, which is the first of a series of reactions in most glucose metabolism pathways. In pancreatic β cells GCK plays a unique role as a "glucose sensor". It is important in glucose-stimulated insulin secretion (GSIS), as it affects the regulation of the glucose-stimulated insulin secretion-threshold (GSIS-T) [10] . Inactivating mutations cause an increase of GSIS-T.
In heterozygous mutation carriers mild fasting hyperglycaemia is observed, whereas homozygotes or mixed heterozygotes are characterised by severe diabetes. The phenotype of GCK deficiency manifests as MODY2 diabetes [11, 12] , and the total loss of protein function leads to permanent neonatal diabetes mellitus (PNDM) [12, 13] . The opposite phenotypic effect occurs in activating mutation carriers. The GSIS-T value is reduced, which in turn leads to a pathological increase in blood insulin, causing hypoglycaemia, with severity depending on the type of mutation occurring in the gene [10, [14] [15] [16] .
Most common changes correlated with hypoglycaemia are located within a small protein domain, bearing the binding site for its allosteric activator [12] .
GLUD-1
The second most common cause of hyperinsulinaemia is malfunction of glutamate dehydrogenase (GDH), caused by mutations in its gene, GLUD-1. GDH is a mitochondrial enzyme that catalyses the reaction of glutamate conversion into α-ketoglutarate and ammonium ions. In pancreatic β cells it is involved in the regulation of insulin secretion. It is allosterically activated by binding ADP, NAD + , and leucine, and inhibited by binding ATP, GTP, NADH, and palmitoylCoA [17] . Mutations preventing the inhibition of GDH by GTP attachment lead to increased stimulation of the enzyme by leucine. The ATP/ADP ratio in the cell increases, and the potassium pump is stopped. This leads to membrane depolarisation and calcium influx into the cell, and consequently to insulin secretion [18] .
GDH dysfunctions are caused in 70% of cases by mutations occurring de novo, which are autosomally dominant [19] . They occur most frequently in the allosteric GTP binding site or within the antenna region involved in the communication with the other subunits of the enzyme -most frequently in exons 6, 7, 11, and 12 [4, 20] . Mutations lead to hyperinsulinaemia/hyperammonaemia syndrome. In carriers there is a fasting and protein-induced hypoglycaemia, which is easily controlled by diazoxide. In addition, higher activity of liver GDH causes a 3-5-fold increase in the blood ammonia level in relation to physiological values [21] .
HADH-1
The observed phenotype of FHI can also be due to impaired fatty acid metabolism. The mitochondrial enzyme 3-hydroxyacyl-coenzyme A dehydrogenase (SCHAD) catalyses the dehydrogenation of 3-hydroxyacyl-CoA to 3-ketoacyl-CoA in the presence of NAD + , the next-to-last reaction in the process of β-oxidation of fatty acids [22] . It plays a significant, although still unexplored, role in the regulation of insulin secretion [23, 24] . In people with lost protein function caused by autosomal recessive HADH-1 gene mutations, there are significant abnormalities (increase) in insulin secretion [25] [26] [27] [28] . Another interesting described effect of loss-of-function HADH-1 mutations is severe overreactivity to leucine [25] . This suggests that -in an as yet unexplained way -insulin secretion is reduced in leucine-stimulated pancreatic β cells. Reports suggest a protein-protein interaction between HADH and GDH. However, mutations in the HADH-1 gene did not result in an increased activity of GDH or changed GTP concentration that would cause GDH inhibition (IC 50 ) [25] . The authors suggested that the observed phenomenon may be due to SCHAD interaction through a new, as yet unrecognised, pathway in which GTP is not involved in the regulation of GDH [25] .
SLC16A1
Hyperinsulinaemia induced by physical activity is associated with autosomal dominant inherited mutations in the promoter region of the gene SLC16A1. Mutations cause an increase of membrane expression of the monocarboxylic acid transporter in β cells [29] . Under normal conditions MCT1 expression is silenced by miR29a and miR29b, and therefore remains at a very low level [30] . Its increase enables the penetration of more substrates for ATP production into the cell -pyruvate and lactate. Consequently, the ATP/ADP ratio in the cytoplasm grows, which implies a number of subsequent events that result in the release of insulin from the cell. In patients who are carriers of SLC16A1 mutations, hypoglycaemia is directly connected to the accumulation of pyruvate and lactate in the blood, caused by intense exercise [29] .
HNF4A/HNF1A
The protein encoded by the gene HNF4A is a nuclear transcription factor that binds to DNA as a homodimer. It is a key protein in the transcriptional hierarchy in the β cell and plays role in multiple processes that are essen-tial for β-cell functioning. It controls the transcription of insulin gene and other genes involved in transport and glucose metabolism [31] . Heterozygotic autosomal dominant mutations in HNF4A have been associated with maturity-onset diabetes of the young, type 1 (MODY1), but also with macrosomia and transient, as well as stable hyperinsulinaemic hypoglycaemia. Over 35% are de novo mutations [32] [33] [34] .
Another gene also encoding a nuclear transcription factor the mutations of which are associated with infant hyperinsulinism is HNF1A [35] . This gene has previously been connected to MODY3. It encodes hepatocyte nuclear factor 1 alpha (HNF1A), an atypical homeodomain-containing protein that regulates the expression of several hepatic genes [36] .
So far it has been impossible to define the mechanism of how loss-of-function mutations in both HNF4A and HNF1A lead to two completely opposing phenotypes in one patient: hypoglycaemia in early life and diabetes in later life. It has been suggested that this may be caused by a change in gene expression regulation by these factors during the patient's life [37] .
UCP2
Mitochondrial uncoupling protein 2 (UCP2) is a member of a large family of mitochondrial proteins that function as anion carriers (MACP) and separate oxidative phosphorylation from ATP synthesis. This process proceeds with energy loss, the so-called mitochondrial proton leak. In the cell MACP proteins are responsible for the transport of anions from the inner to the outer mitochondrial membrane, and protons in the opposite direction. UCP2 is therefore responsible for the controlled leak of electrons from the inner mitochondrial membrane [38] , which leads to the decrease of ATP in the cell. In case of pancreatic β cells this additionally leads to negative GSIS regulation [39] .
Mutations of the UCP2 promoter region cause a decrease in insulin secretion and have been associated with a higher risk of type 2 diabetes [40, 41] . Conversely, mutations inside the gene UCP2I, being loss-of-function mutations, cause an increase of ATP, which leads to excessive insulin production, and therefore hyperinsulinism [42] . Additionally, UCP2 has been shown to be important for the negative regulation of glucose sensing in neurons [43] .
Discussion
Knowledge of the genetic background of hyperinsulinaemic hypoglycaemia allows for a better understanding of the mechanism of this disease, which has a very similar clinical outcome in different patients, all resulting in hypoglycaemia. Even using advanced imaging techniques, including methods based on PET (photoinduced electron transfer) or pathological examination [44] , an early diagnosis of familial hyperinsulinaemia is difficult or even impossible.
It is the molecular level that allows for the precise understanding of the disease's background. The huge progress that has been made in recent years in the understanding of the pathogenesis of hyperinsulinaemia has allowed a closer look at the problem of infant hypoglycaemia and the differentiation of separate diseases that have previously been considered to be one, termed nesidioblastosis. Genetics also allows us to predict which patients will benefit from diazoxide treatment, and which of them will remain unresponsive to this therapy (see Table I ). We cannot be certain that the results of genetic research will lead us to a conscious use of medications that have not correlated with hyperinsulinaemic hypoglycaemia so far, for example: calcium channel blockers (verapamil, amlodipine) [45, 46] . The research that has been performed so far, although being of invaluable importance, does not exhaust this topic, because the number of patients in which no mutation in any of the described genes can be found accounts for about 45% [47] , which means that over half of the analysed cases remain with an unknown reason for their disease.
Molecular diagnostics are costly and time-consuming, and therefore the availability of these examinations is restricted. Molecular methods are not first-line tests in the case of FHI suspicion. However, bearing in mind their huge diagnostic value as well as the possibilities offered by next-generation sequencing devices, it seems possible that for proper planning the importance of molecular methods in nesidioblastosis diagnostics may rise in the near future. 
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3-hydroksyacyloCoA
SLC16A1/MCT1
Transporter kwasów monokarboksylowych 1
HNF4A, HNF1A
Czynnik jądrowy hepatycytów 4α i 1α > ciężka postać hipoglikemii noworodków [48, 49] > rozlane FHI** [6] -dominujące:
UCP2
Mitochon
> postać umiarkowana [48, 49] > ogniskowa postać FHI -powodowana ojcowską mutacją jednego z genów i utratą allelu matczynego [8] Dominujące, aktywujące [10, [14] [15] [16] Dominujące, aktywujące [4, 19] Relatywnie umiarkowana postać FHI, może nie zostać rozpoznana w dzieciństwie [20] Recesywne, utrata funkcji [4, [25] [26] [27] [28] Dominujące, zwiększona ekspresja [29] Dominujące, utrata funkcji [35] Zasocjowane z MODY1 [HNF4a] i MODY3 [HNF1a] [35] Dominujące, utrata funkcji
Charakterys tyka
Duża masa urodzeniowa [4] Zwiększone ryzyko cukrzycy w wieku dorosłym [4] Normalna masa urodzeniowa [15] Hyperammonemia [21] Leucyno zależna hipoglikemia białkiem [4] Zwiększone wydalanie kwasu 3-hydroksyglutarowego [4] Leucyno zależna hipoglikemia stymulowana białkiem [25] Hipoglikemia po intensywnych ćwiczeniach [29] Duża masa urodzeniowa [34] Rozwój z hiperinsulinemizmu w niemowlęctwie do cukrzycy w wieku później szym [34, 35] *Przypadki z dominującymi mutacjami KATP mogą reagować na leczenie diazoksydem [48, 49] . **Większość przypadków. Dominujące mutacje w rozlanej postaci FHI również były obserwowane [6] 
